LEXISCAN

LOE Approaching

regadenoson

NDAINTRAVENOUSSOLUTION
Approved
Apr 2008
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20

Mechanism of Action

Adenosine Receptor Agonists

Pharmacologic Class:

Adenosine Receptor Agonist

Clinical Trials (5)

NCT03103061Phase 2Completed

Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System

Started Feb 2016
24 enrolled
Cardiovascular DiseasesCoronary Artery Disease
NCT02130453Phase 4Completed

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Started Sep 2014
Ischemia
NCT02220634N/ATerminated

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

Started Aug 2014
10 enrolled
Pulmonary Hypertension
NCT01918995Phase 1Completed

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Started May 2013
36 enrolled
Healthy Volunteers
NCT01842035N/ACompleted

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Started Feb 2013
Left Ventricular Systolic DysfunctionSudden Cardiac Death

Loss of Exclusivity

LOE Date
Feb 2, 2027
11 months away
Patent Expiry
Feb 2, 2027

Patent Records (2)

Patent #ExpiryTypeUse Code
8106183
Feb 2, 2027
Substance
RE47301
Feb 2, 2027
Product